Guerbet SA (LON:0ELV)

Market Cap	153.90M -46.2%
Revenue (ttm)	703.68M -2.4%
Net Income	6.63M -76.4%
EPS	0.53 -76.3%
Shares Out	n/a
PE Ratio	23.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	19
Open	14.18
Previous Close	13.76
Day's Range	14.10 - 14.18
52-Week Range	11.96 - 28.05
Beta	0.76
RSI	47.07
Earnings Date	Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 1926
• Employees: 2,905
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ELV

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.

Financial numbers in EUR